Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
natural symbols : Celu save search
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
Published: 2024-04-08 (Crawled : 13:00) - globenewswire.com
CELU | News 4 | $3.38 5.3% 5.17% 36K
|
|
| O: 5.51%
H: 5.78%
C: 3.36%
natural cell
Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
Published: 2022-11-10 (Crawled : 14:20) - globenewswire.com
CELU | News 4 | $3.38 5.3% 5.17% 36K
|
|
| O: 3.23%
H: 15.63%
C: 10.94%
cynk-101 preclinical immunotherapy meeting therapy
Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro
Published: 2022-09-26 (Crawled : 14:00) - biospace.com/
CELU | News 4 | $3.38 5.3% 5.17% 36K
|
|
| O: -1.99%
H: 5.08%
C: 3.66%
immunology virus influenza in vitro
Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform
Published: 2022-07-19 (Crawled : 12:20) - biospace.com/
CELU | News 4 | $3.38 5.3% 5.17% 36K
|
|
| O: 1.39%
H: 0.55%
C: -4.37%
research collaboration antibody potential platform
Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition
Published: 2021-12-13 (Crawled : 15:30) - biospace.com/
CELU | News 4 | $3.38 5.3% 5.17% 36K
|
|
| O: -1.42%
H: 0.0%
C: 0.0%
ema genetic preclinical therapy pre-clinical
Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer
Published: 2021-11-29 (Crawled : 14:30) - biospace.com/
CELU | News 4 | $3.38 5.3% 5.17% 36K
|
|
| O: 1.48%
H: 2.19%
C: -2.19%
new drug fda clearance application drug fda clearance positive therapy cancer her2- her2
Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting
Published: 2021-11-15 (Crawled : 13:30) - globenewswire.com
CELU | News 4 | $3.38 5.3% 5.17% 36K
|
|
| O: -1.8%
H: 0.0%
C: -4.22%
preclinical genetic immunotherapy therapy cancer pre-clinical
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.